• ChemFaces is a professional high-purity natural products manufacturer.
  • Product Intended Use
  • 1. Reference standards
  • 2. Pharmacological research
  • 3. Inhibitors
  • Home
  • Natural Products
  • Bioactive
  • Screening Libraries
  • Hot Products
  • Plant Catalog
  • Customer Support
  • Product Use Citation
  • About Us
  • Contact Us
  • Natural Products
    Artemisinic acid
    CAS No. 80286-58-4 Price $80 / 20mg
    Catalog No.CFN97276Purity>=98%
    Molecular Weight234.3 Type of CompoundSesquiterpenoids
    FormulaC15H22O2Physical DescriptionPowder
    Download Manual    COA    MSDSSimilar structuralComparison (Web)
    How to Order
    Orders via your E-mail:

    1. Product number / Name / CAS No.
    2. Delivery address
    3. Ordering/billing address
    4. Contact information
    Sent to Email: info@chemfaces.com
    Contact Us
    Order & Inquiry & Tech Support

    Tel: (0086)-27-84237683
    Fax: (0086)-27-84254680
    E-mail: manager@chemfaces.com
    Address: No. 83, CheCheng Rd., WETDZ, Wuhan, Hubei 430056, PRC
    Delivery time
    Delivery & Payment method

    1. Usually delivery time: Next day delivery by 9:00 a.m. Order now

    2. We accept: Wire transfer & Credit card & Paypal & Western Union
    * Packaging according to customer requirements(5mg, 10mg, 20mg and more). We shipped via FedEx, DHL, UPS, EMS and others courier.
    Our products had been exported to the following research institutions and universities, And still growing.
  • Istanbul University (Turkey)
  • Universiti Malaysia Pahang (Malaysia)
  • University of Dicle (Turkey)
  • Helmholtz Zentrum München (Germany)
  • Texas A&M University (USA)
  • National Cancer Institute (USA)
  • University of Leipzig (Germany)
  • University of Bonn (Germany)
  • Mahidol University (Thailand)
  • Universiti Sains Malaysia (Malaysia)
  • Subang Jaya Medical Centre (Malaysia)
  • More...
  • Package
    Featured Products
    Polygalaxanthone III

    Catalog No: CFN90208
    CAS No: 162857-78-5
    Price: $138/20mg

    Catalog No: CFN92377
    CAS No: 638-95-9
    Price: $318/5mg

    Catalog No: CFN98958
    CAS No: 569-83-5
    Price: $60/20mg

    Catalog No: CFN99106
    CAS No: 40957-83-3
    Price: $128/20mg
    Ganoderiol F

    Catalog No: CFN99244
    CAS No: 114567-47-4
    Price: $398/5mg
    Biological Activity
    Description: Artemisinic acid, is the immediate precursor of the semi-synthesis artemisinin, could be a cost-effective, environmentally friendly, high-quality and reliable source of artemisinin. Artemisinic acid has a variety of pharmacological activity, such as antimalarial, anti-tumor, antipyretic, antibacterial, allelopathy and anti-adipogenesis effects. Artemisinic acid is a regulator of adipocyte differentiation and C/EBP δ expression, it inhibits adipogenic differentiation of hAMSCs through reduced expression of C/EBP δ; it inhibits melanogenesis through downregulation of C/EBP α-dependent expression of HMG-CoA reductase gene.
    Targets: Tyrosinase | cAMP | PKA | HMG-CoA Reductase | PPAR | JNK | VEGFR | P450 (e.g. CYP17) | Antifection | C/EBP δ
    In vitro:
    J Cell Biochem. 2012 Jul;113(7):2488-99.
    Artemisinic acid is a regulator of adipocyte differentiation and C/EBP δ expression.[Pubmed: 22396222]
    Adipocyte dysfunction is associated with the development of obesity. In this study, Artemisinic acid, which was isolated from Artemisia annua L., inhibited adipogenic differentiation of human adipose tissue-derived mesenchymal stem cells (hAMSCs) and its mechanism of action was determined.
    The mRNA levels of peroxidase proliferation-activated receptor (PPAR) γ and CCAAT/enhancer binding protein (C/EBP) α, late adipogenic factors, were reduced by Artemisinic acid. Moreover, the mRNA levels of the PPAR γ target genes lipoprotein lipase, CD36, adipocyte protein, and liver X receptor were down-regulated by Artemisinic acid. Artemisinic acid reduced expression of the C/EBP δ gene without impacting C/EBP β. In addition, attempts to elucidate a possible mechanism underlying the Artemisinic acid-mediated effects revealed that reduced expression of the C/EBP δ gene was mediated by inhibiting Jun N-terminal kinase (JNK). Additionally, Artemisinic acid also reduced the expression of the adipogenesis-associated genes glucose transporter-4 and vascular endothelial growth factor. In addition to the interference of Artemisinic acid with adipogenesis, Artemisinic acid significantly attenuated tumor necrosis factor-α-induced secretion of interleukin-6 by undifferentiated hAMSCs, thus influencing insulin resistance and the inflammatory state characterizing obesity.
    Taken together, these findings indicate that inhibiting adipogenic differentiation of hAMSCs by Artemisinic acid occurs primarily through reduced expression of C/EBP δ, which is mediated by the inhibition of JNK and suggest that aremisinic acid may be used as a complementary treatment option for obesity associated with metabolic syndrome.
    Current Science, 2000 , 78 (6) :709-713.
    Antimicrobial activity of artemisinin and its precursors.[Reference: WebLink]
    Artemisinic acid and Arteannuin B are biogenetic precursors of Artemisinin, an important antimalarial produced by the herb Artemisia annua. These compounds have been screened for antimicrobial activity against a range of organisms.
    All the three compounds are active against different bacteria and certain fungal species
    Artemisinic acid Description
    Source: The herbs of Artemisia annua L.
    Solvent: Chloroform, Dichloromethane, Ethyl Acetate, DMSO, Acetone, etc.
    Storage: Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 24 months(2-8C).

    Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.

    Need more advice on solubility, usage and handling? Please email to: service@chemfaces.com

    After receiving: The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.
    Recent ChemFaces New Products and Compounds

    Catalog No: CFN93276
    CAS No: 548-76-5
    Price: $238/20mg

    Catalog No: CFN98733
    CAS No: 480-10-4
    Price: $138/20mg
    20-O-Glucoginsenoside Rf

    Catalog No: CFN95036
    CAS No: 68406-27-9
    Price: $368/10mg

    Catalog No: CFN95009
    CAS No: 76844-70-7
    Price: $368/5mg

    Catalog No: CFN90838
    CAS No: 733-40-4
    Price: $388/10mg
    Iristectorin A

    Catalog No: CFN95037
    CAS No: 37744-61-9
    Price: $333/5mg
    Pachymic acid

    Catalog No: CFN99590
    CAS No: 29070-92-6
    Price: $268/20mg
    Atractylenolide III acetate

    Catalog No: CFN95078
    CAS No: N/A
    Price: $413/5mg
    Recently, ChemFaces products have been cited in many studies from excellent and top scientific journals

    Cell. 2018 Jan 11;172(1-2):249-261.e12.
    doi: 10.1016/j.cell.2017.12.019.

    PMID: 29328914

    Mol Cell. 2017 Nov 16;68(4):673-685.e6.
    doi: 10.1016/j.molcel.2017.10.022.

    PMID: 29149595

    Scientific Reports 2017 Dec 11;7(1):17332.
    doi: 10.1038/s41598-017-17427-6.

    PMID: 29230013

    Molecules. 2017 Oct 27;22(11). pii: E1829.
    doi: 10.3390/molecules22111829.

    PMID: 29077044

    J Cell Biochem. 2018 Feb;119(2):2231-2239.
    doi: 10.1002/jcb.26385.

    PMID: 28857247

    Phytomedicine. 2018 Feb 1;40:37-47.
    doi: 10.1016/j.phymed.2017.12.030.

    PMID: 29496173
    Calculate Dilution Ratios(Only for Reference)
    1 mg 5 mg 10 mg 20 mg 25 mg
    1 mM 4.268 mL 21.3402 mL 42.6803 mL 85.3606 mL 106.7008 mL
    5 mM 0.8536 mL 4.268 mL 8.5361 mL 17.0721 mL 21.3402 mL
    10 mM 0.4268 mL 2.134 mL 4.268 mL 8.5361 mL 10.6701 mL
    50 mM 0.0854 mL 0.4268 mL 0.8536 mL 1.7072 mL 2.134 mL
    100 mM 0.0427 mL 0.2134 mL 0.4268 mL 0.8536 mL 1.067 mL
    * Note: If you are in the process of experiment, it's need to make the dilution ratios of the samples. The dilution data of the sheet for your reference. Normally, it's can get a better solubility within lower of Concentrations.
    Kinase Assay:
    Food Chem Toxicol. 2013 Jan;51:225-30.
    Artemisinic acid inhibits melanogenesis through downregulation of C/EBP α-dependent expression of HMG-CoA reductase gene.[Pubmed: 23063590]
    Cholesterol is associated with the regulation of melanogenesis which is the major physiological defense against solar irradiation. The present study was designed to determine the effects of Artemisinic acid on melanogenesis and its mechanisms of action in human epidermal melanocytes.
    In this study, we found that Artemisinic acid inhibited melanin content. The mRNA levels of microphthalmia-associated transcription factor (MITF) and its downstream genes tyrosinase, tyrosinase-related protein (TRP)-1, and TRP-2 were reduced by Artemisinic acid treatment. Additionally, the mRNA levels of melanogenesis-related genes (c-KIT, stem cell factor (SCF), and macrophage migration inhibitory factor (MIF)) were down-regulated by Artemisinic acid. Furthermore, cAMP production and protein kinase A (PKA) activity were suppressed by Artemisinic acid. Moreover, attempts to elucidate a possible mechanism underlying the Artemisinic acid-mediated effects revealed that Artemisinic acid regulated melanogenesis by inhibiting cholesterol synthesis through downregulation of the hydroxymethylglutaryl CoA (HMG CoA) reductase gene, which was mediated through reduced expression of the CCAAT/enhancer-binding protein (C/EBP) α gene.
    Taken together, these findings indicate that the inhibition of melanogenesis by Artemisinic acid occurs through reduced expression of the HMG CoA reductase gene, which is mediated by C/EBP α inhibition and suggest that Artemisinic acid may be useful as a hyperpigmentation inhibitor.
    Structure Identification:
    Nature. 2006 Apr 13;440(7086):940-3.
    Production of the antimalarial drug precursor artemisinic acid in engineered yeast.[Pubmed: 16612385 ]
    Malaria is a global health problem that threatens 300-500 million people and kills more than one million people annually. Disease control is hampered by the occurrence of multi-drug-resistant strains of the malaria parasite Plasmodium falciparum. Synthetic antimalarial drugs and malarial vaccines are currently being developed, but their efficacy against malaria awaits rigorous clinical testing. Artemisinin, a sesquiterpene lactone endoperoxide extracted from Artemisia annua L (family Asteraceae; commonly known as sweet wormwood), is highly effective against multi-drug-resistant Plasmodium spp., but is in short supply and unaffordable to most malaria sufferers. Although total synthesis of artemisinin is difficult and costly, the semi-synthesis of artemisinin or any derivative from microbially sourced Artemisinic acid, its immediate precursor, could be a cost-effective, environmentally friendly, high-quality and reliable source of artemisinin.
    Here we report the engineering of Saccharomyces cerevisiae to produce high titres (up to 100 mg l(-1)) of Artemisinic acid using an engineered mevalonate pathway, amorphadiene synthase, and a novel cytochrome P450 monooxygenase (CYP71AV1) from A. annua that performs a three-step oxidation of amorpha-4,11-diene to Artemisinic acid. The synthesized Artemisinic acid is transported out and retained on the outside of the engineered yeast, meaning that a simple and inexpensive purification process can be used to obtain the desired product.
    Although the engineered yeast is already capable of producing Artemisinic acid at a significantly higher specific productivity than A. annua, yield optimization and industrial scale-up will be required to raise Artemisinic acid production to a level high enough to reduce artemisinin combination therapies to significantly below their current prices.